These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22377784)

  • 21. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer's disease.
    Tran TT; Srivareerat M; Alkadhi KA
    Neurobiol Dis; 2010 Mar; 37(3):756-63. PubMed ID: 20044001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons.
    Chiba T; Yamada M; Sasabe J; Terashita K; Shimoda M; Matsuoka M; Aiso S
    Mol Psychiatry; 2009 Feb; 14(2):206-22. PubMed ID: 18813209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of beta-amyloid protein on calcium channels in plasma membranes of cultured hippocampal neurons].
    Korol' TIu; Kostiuk OP; Kostiuk PH
    Fiziol Zh (1994); 2009; 55(4):10-6. PubMed ID: 19827625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease.
    Smith IF; Hitt B; Green KN; Oddo S; LaFerla FM
    J Neurochem; 2005 Sep; 94(6):1711-8. PubMed ID: 16156741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presenilins as endoplasmic reticulum calcium leak channels and Alzheimer's disease pathogenesis.
    Supnet C; Bezprozvanny I
    Sci China Life Sci; 2011 Aug; 54(8):744-51. PubMed ID: 21786197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease.
    Hung CH; Ho YS; Chang RC
    Ageing Res Rev; 2010 Oct; 9(4):447-56. PubMed ID: 20553970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyhistidine peptide inhibitor of the Abeta calcium channel potently blocks the Abeta-induced calcium response in cells. Theoretical modeling suggests a cooperative binding process.
    Arispe N; Diaz J; Durell SR; Shafrir Y; Guy HR
    Biochemistry; 2010 Sep; 49(36):7847-53. PubMed ID: 20690616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of large-conductance Ca(2+)-activated K(+) channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice.
    Ye H; Jalini S; Mylvaganam S; Carlen P
    Neurobiol Aging; 2010 Apr; 31(4):591-604. PubMed ID: 18547679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise.
    Mattson MP
    Ann N Y Acad Sci; 1994 Dec; 747():50-76. PubMed ID: 7847692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction.
    Chakroborty S; Stutzmann GE
    Sci China Life Sci; 2011 Aug; 54(8):752-62. PubMed ID: 21786198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: a comprehensive review of evidences.
    Saravanaraman P; Chinnadurai RK; Boopathy R
    Rev Neurosci; 2014; 25(2):231-46. PubMed ID: 24566363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction?
    Bergantin LB
    Curr Hypertens Rev; 2019; 15(1):32-39. PubMed ID: 30117399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium channel blockers and dementia.
    Nimmrich V; Eckert A
    Br J Pharmacol; 2013 Jul; 169(6):1203-10. PubMed ID: 23638877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Interactions Between Alzheimer's Disease and Major Depression: Role of Ca
    Bergantin LB
    Curr Drug Res Rev; 2020; 12(2):97-102. PubMed ID: 32065096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?
    Corbett A; Ballard C
    Expert Opin Investig Drugs; 2013 Aug; 22(8):941-3. PubMed ID: 23808708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium channel blockers' contribution to overcoming Current drug discovery challenges in Alzheimer's disease.
    Bernard PJ; Bellili D; Ismaili L
    Expert Opin Drug Discov; 2024; 19(1):21-32. PubMed ID: 37800853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures.
    Chakroborty S; Stutzmann GE
    Eur J Pharmacol; 2014 Sep; 739():83-95. PubMed ID: 24316360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal.
    Harrison PJ; Tunbridge EM; Dolphin AC; Hall J
    Br J Psychiatry; 2020 May; 216(5):250-253. PubMed ID: 31230606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.